Physician profile
Stuart Milan
NPI 1689766958
$2,439.91
in general payments reported to CMS, 2019-2025
12 companies · $919 in 2025
The $919 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.80 · 2022: $546 · 2023: $473 · 2024: $453 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.71 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $417.22 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $265.27 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $242.46 | 2024-2025 | Auvelity |
| Indivior INC. | $237.99 | 2022-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $91.05 | 2023-2025 | Spravato |
| Alkermes, INC. | $88.70 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $61.94 | 2023-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $33.45 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.47 | 2025 | Caplyta |
| Braeburn INC. | $18.25 | 2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Milan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.